Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATI-450 + Capecitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATI-450 | CDD-450|MK2Pi|Zunsemetinib | ATI-450 is a small molecule that selectively inhibits MK2 (MAPKAPK2) activation by p38alpha (MAPK14), potentially leading to reduced metastatic tumor growth (PMID: 30093561, PMID: 29549113). | ||
Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06374459 | Phase Ib/II | ATI-450 + Capecitabine Capecitabine + Zoledronic acid Capecitabine + Denosumab | Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis | Not yet recruiting | USA | 0 |